John Dunlop

Head of Research and Development, Neumora

Prior to Neumora, Dunlop led the neuroscience research program responsible for therapeutic discovery activities in neurodegenerative diseases, pain and migraine. Prior to Amgen, he led neuroscience discovery and early development at AstraZeneca and previously held executive leadership roles in neuroscience at Wyeth and Pfizer.

Trained as a neuropharmacologist, Dunlop’s research interests include the role of protein quality control mechanisms, innate immunity, and mitochondrial dysfunction in brain diseases. He is a board member of Target-ALS, a non-profit enterprise dedicated to accelerating drug discovery and development in ALS, and MassBio, and is on the scientific advisory boards of Vigil Neuroscience and the Packard Center for ALS Research at Johns Hopkins.